FDA-Approved Radiopharmaceutical Supplies and Nuclear Medicine Cold Kits
Overview
- Response deadline
- 5:00 PM EDT
- Posted
- August 10, 2026
- Notice type
- Presolicitation
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDEFENSE HEALTH AGENCY (DHA)
Notice details
- Office
- DEFENSE HEALTH AGENCY
- Place of performance
- Fort Gordon, Georgia, 30905
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- PANHCA26P0000030882
- Notice ID
- eaab74a049294a0ba242cf7c8fefa2c2
Description
FDA-Approved Radiopharmaceutical Supplies and Nuclear Medicine Cold Kits
Dwight David Eisenhower Army Medical Center (DDEAMC), Fort Eisenhower, GA
DISCLAIMER
This is a Pre-solicitation Notice (Synopsis of Proposed Contract Action) to identify potential sources possessing the capabilities described herein. This Pre-solicitation Notice is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offer will be considered in response to this Pre-solicitation Notice. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract.
Responders are solely responsible for all expenses associated with responding to this NOTICE or any follow-up information request. All information received in response to this NOTICE that is marked "Proprietary" will be handled accordingly. Responses to the NOTICE will not be returned. At this time, questions concerning the composition and requirements for a future solicitation will not be entertained.
NOTE: At this time, no solicitation exists. Therefore, please do not request a copy of a solicitation. NO PHONE CALLS WILL BE ACCEPTED. It is the responsibility of any potential Offeror to monitor the SAM.gov site for the release of any subsequent solicitation.
1. NOTICE TITLE
FDA-Approved Radiopharmaceutical Supplies and Nuclear Medicine Compounding Cold Kits for Dwight David Eisenhower Army Medical Center (DDEAMC).
2. PLACE OF PERFORMANCE (LOCATION)
Dwight David Eisenhower Army Medical Center (DDEAMC)
300 Hospital Road, Fort Eisenhower, Georgia 30905-5650
3. BACKGROUND
The Nuclear Medicine Section at DDEAMC requires a continuous, and reliable supply of Federal Drug Administration (FDA) approved active radiopharmaceuticals "hot doses" and non-radioactive compounding "cold kits."
Currently, these requirements are satisfied under separate contracts. The Government intends to combine the active/hot doses, and the cold kit supplies, into a single, consolidated firm-fixed-price commercial contract.
4. DESCRIPTION & CLASSIFICATION
The Contractor shall provide all necessary compounding facilities, certified personnel, USP-compliant cleanrooms, quality control testing, transportation, DOT-compliant vehicles, shielding, and related delivery accessories to fulfill routine and emergency nuclear medicine orders.
A copy of the Draft Performance Work Statement (PWS) detailing the complete itemized workload and consolidated performance standards is attached to this NOTICE. Industry is highly encouraged to review the PWS and provide feedback or capability questions as part of their response.
- NAICS Code: 325412 – Pharmaceutical Preparation Manufacturing
- Size Standard: 1,250 Employees (SBA Manufacturing Standard)
- Product Service Code (PSC): 6505 – Drugs and Biologicals
5. CRITICAL LOGISTICAL REQUIREMENTS (NON-NEGOTIABLE)
Due to the physics of isotopic decay and the critical nature of patient-care delivery timelines, the following logistical parameters are strict, non-negotiable, and must be met for a contractor to be deemed capable:
- The contractor’s nuclear compounding pharmacy facility must be physically located within a 90-minute driving radius of DDEAMC (Fort Eisenhower, GA). This is an absolute safety and technical threshold to prevent isotopic decay prior to delivery.
- Compounded active doses must be packaged and delivered directly to the DDEAMC Nuclear Medicine Service no later than 30 minutes prior to scheduled patient calibration times on an as-needed, 24-hour delivery window.
- The contractor must possess a dedicated 24/7/365 emergency compounding and transport network capable of delivering emergency "hot doses" directly to the DDEAMC Nuclear Medicine department within 2 hours of order acceptance.
6. NOTICE SUBMISSION INSTRUCTIONS
Interested parties possessing the capability to fulfill this consolidated requirement are invited to submit a written capability statement. Submissions shall adhere to the following formatting and outline instructions:
- Submissions must be limited to 5 pages, be sent electronically in Adobe PDF format and must include:
- Company Name, Address, and Point of Contact (Name, Title, Phone, and Email).
- CAGE Code and Unique Entity Identifier (UEI) registered in SAM.gov.
- Business Size Status under NAICS 325412 (e.g., Large Business, Small Business, SDVOSB, WOSB, HUBZone).
- Capability Statement Outline:
- Provide a detailed description of your facility's capability to compound and supply both active radiopharmaceuticals ("hot doses") and non-radioactive cold kits simultaneously as outlined in standard clinical nuclear pharmacy models.
- Explicitly demonstrate and verify how your facility will comply with the non-negotiable 90-minute compounding driving radius and the 2-hour emergency delivery timeline on a 24/7/365 basis. Specify the physical address of the compounding pharmacy that would support this contract.
- Confirm your facility’s active licensing and compliance with FDA, Nuclear Regulatory Commission (NRC), Department of Transportation (DOT), USP <797>, and USP <825> sterile compounding standards.
- Identify any current federal contract vehicles (e.g., GSA Schedules, VA FSS, or DoD enterprise-wide contracts) under which you currently offer these supplies.
- State whether your firm currently provides these identical compounding and delivery services to the general public or local commercial hospital systems under similar terms and conditions.
7. SUBMISSION DEADLINE AND POCs
Responses to this NOTICE must be submitted no later than August 14, 2026, at 5:00 PM Eastern Daylight Time (EDT).
Submissions shall be emailed directly to the following Contracting Points of Contact:
- Sherina Ross (Contract Specialist): sherina.l.ross.civ@health.mil
- Michael Heaney (Contract Specialist: michael.s.heaney2.civ@health.mil
- Lenore Paseda (Contracting Officer): lenore.y.paseda.civ@health.mil
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (1)
- Download
Performance_Work_Statement__FDA-Approved_Radiopharmaceutical_Supplies.pdf
186 KBAdded in Presolicitation version 3Posted
Lifecycle
- 3Version 3PresolicitationArchivedCurrent
FDA-Approved Radiopharmaceutical Supplies and Nuclear Medicine Cold Kits
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | 66% | Solicitation | 11/30/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | 66% | Solicitation | 12/07/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | 66% | Solicitation | 10/26/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Furoscix ReadyFlow – Diuretics – NA b. Gwyn Lo – Contraceptive Agents – Miscellaneous c. Jideytro – Lung Cancer – NA d. Omlyclo – Atopy – NA e. RizaFilm – Migraine Agents – NA f. Zenbexus – Multiple Myeloma – NA The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9403. Pre-Quotation Teleconference is on September 9, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | 66% | Solicitation | 09/24/2026 |
The Defense Health Agency (DHA) Contracting Activity (DHACA), on behalf of the DHA’s Portfolio Acquisition Executive Medical Products (PAE MP), intends to issue a firm-fixed price Indefinite Delivery/Indefinite Quantity contract on a sole source basis under the authority of the Revolutionary Federal Acquisition Regulation (FAR) Overhaul, FAR 6.103-1, only one responsible source and no other supplies or services will satisfy agency requirements, to Vascular Solutions LLC, 6420 Sycamore Ct N, Maple Grove, Minnesota 55369-6032. Vascular Solutions, LLC is the only source able to meet the Government’s requirements. The Government has a has a critical requirement for supply of a Food and Drug Administration (FDA) approved Freeze Dried Plasma (FDP) product for transfusion when plasma is required and other plasma products are not available. The FDA approved Vascular Solutions, LLC FDP product, EZPLAZ™, on 29 July 2026. Vascular Solutions LLC holds the first and only FDA-approved (licensed) FPD product on the market. This Notice of Intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Responses must be supported with clear and convincing evidence articulating the ability to provide FDA approved FDP product. Capability statements shall not exceed 5 (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract. If no written responses are received by the date listed below, an Indefinite Delivery/Indefinite Quantity contract will be awarded without further remark. Capability statements are due by 3:00 PM local time, 16 September 2026. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: timothy.j.kelly169.civ@health.mil and shannon.p.lertora.civ@health.mil. | 66% | Special Notice | 09/16/2026 |
Additional Details
Solicitation Number
PANHCA26P0000030882
Archive Date
Aug 29, 2026
Office Address
FREDERICK, MD, 21702